{"id":294263,"date":"2026-04-21T00:00:00","date_gmt":"2026-04-21T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrcg0015-2024-biopharma-major-depressive-disorder-dsm-v-current-treatment-current-treatment\/"},"modified":"2026-05-16T11:13:54","modified_gmt":"2026-05-16T11:13:54","slug":"cutrcg0015-2026-biopharma-major-depressive-disorder-dsm-v-current-treatment-current-treatment-physician-insights","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrcg0015-2026-biopharma-major-depressive-disorder-dsm-v-current-treatment-current-treatment-physician-insights\/","title":{"rendered":"Major Depressive Disorder (DSM-V) &#8211; Current Treatment &#8211; Current Treatment: Physician Insights \u2013 Major Depressive Disorder (EU5)"},"content":{"rendered":"<p>Across the <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>, the treatment landscape for major depressive disorder (<abbr title=\"major depressive disorder\">MDD<\/abbr>) is shaped by the widespread use of <abbr title=\"selective serotonin reuptake inhibitor\">SSRI<\/abbr>s and <abbr title=\"serotonin\/norepinephrine reuptake inhibitor\">SNRI<\/abbr>s, which continue to serve as firstline therapy due to their longestablished efficacy, generic availability, and favorable reimbursement positioning. However, branded therapies, including Brintellix (Lundbeck\u2019s vortioxetine) and Spravato (Johnson &#038; Johnson Innovative Medicine\u2019s esketamine), are important treatment alternatives, particularly for treatment-resistant depression (<abbr title=\"treatment-resistant depression\">TRD<\/abbr>). Given the highly genericized nature of the <abbr title=\"major depressive disorder\">MDD<\/abbr> therapy market, the differences in the availability of drugs in the <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>, the heterogeneity of the <abbr title=\"major depressive disorder\">MDD<\/abbr> patient population, and patients\u2019 varied responses to treatment, the prescribing pattern of <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr> psychiatrists and <abbr title=\"general practitioner\">GP<\/abbr>s \/ internists can vary. Understanding the decision points and challenges that physicians face when treating <abbr title=\"major depressive disorder\">MDD<\/abbr> is paramount for marketers of current therapies and developers of emerging therapies to assess the opportunities for drug development in this highly prevalent indication in Europe.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What are the drivers and constraints influencing physicians\u2019 treatment decisions for <abbr title=\"major depressive disorder\">MDD<\/abbr>?<\/li>\n<li>How are patients being treated in various lines of therapy, and what is the patient share of individual therapies?<\/li>\n<li>What percentage of drug-treated <abbr title=\"major depressive disorder\">MDD<\/abbr> patients are partial responders, and what percentage are treatment-resistant? What is the most common course of action for partial responders and <abbr title=\"treatment-resistant depression\">TRD<\/abbr> patients?<\/li>\n<li>To what extent is polypharmacy used for <abbr title=\"major depressive disorder\">MDD<\/abbr> in different lines of therapy in the <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients?<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p>Through survey data from <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr> physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Understand the treatment landscape for a disease and how physicians make prescribing decisions.<\/li>\n<li>Evaluate the drivers and obstacles that influence treatment selection.<\/li>\n<li>Analyze your brand&#8217;s performance from the physician perspective to enhance or defend your competitive position.<\/li>\n<li>Create impactful messaging for physicians by identifying brand differentiators and understanding what motivates prescribing behaviors.<\/li>\n<\/ul>\n<p><b>Geography: <\/b>France, Germany, Italy, Spain, United Kingdom<\/p>\n<p><strong>Primary research: <\/strong>Survey of 125 <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr> psychiatrists and 125 <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr> <abbr title=\"general practitioner\">GP<\/abbr>s \/ internists (25 psychiatrists and 25 <abbr title=\"general practitioner\">GP<\/abbr>s \/ internists per country<\/p>\n<p><strong>Key drugs: <\/strong>Brintellix, Spravato, Reagila, Rxulti, <abbr title=\"selective serotonin reuptake inhibitor\">SSRI<\/abbr>s, <abbr title=\"serotonin\/norepinephrine reuptake inhibitor\">SNRI<\/abbr>s<\/p>\n<p><strong>Key analyses<\/strong><\/p>\n<ul>\n<li>Factors influencing disease management and treatment decisions<\/li>\n<li>Drivers and constraints of treatment selection<\/li>\n<li>Physician-reported treatment practices and brand-level patient shares<\/li>\n<li>Rationale for changes in treatment approach<\/li>\n<li>Physician insight on persistency and compliance<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-294263","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-major-depressive-disorder","biopharma-therapy-areas-psychiatry","biopharma-product-current-treatment","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/294263","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/294263\/revisions"}],"predecessor-version":[{"id":579380,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/294263\/revisions\/579380"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=294263"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}